Dynavax Technologies Corporation (Nasdaq: DVAX) $1.49. Today announced data from two studies that differentiate SD-101 from standard-of-care as well as emerging treatments for chronic HCV infection. The findings of a Phase 1b clinical trial and an in vitro study of SD-101's mechanism of action show that the second-generation TLR9 agonist (1) is well tolerated and safe and (2) induces both IFN-lambda and IFN-alpha at concentrations producing antiviral activity. The data will be presented at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria in April 2010.
What They Do: Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide more rapid and increased protection with fewer doses than current licensed vaccines.
To read more about Dynavax visit http://www.smallcapreview.com/dvax.htm.
Achillion Pharmaceuticals (Nasdaq: ACHN) $2.29. Announced yesterday after market close that Michael D. Kishbauch, Achillion's President and Chief Executive Officer, will lead the Company's management team in hosting a Corporate and Clinical Update conference call on Monday, February 1, 2010 at 4:30 p.m. Eastern time.
Management will bring investors up to date on the Company's progress and plans in its three distinct HCV programs:
Protease inhibitor program featuring ACH-1625, a compound that has recently completed successful proof-of-concept Phase Ib testing, and has demonstrated high potency, unique pharmacokinetic properties and an excellent safety profile;
Novel mechanism NS4A antagonist program featuring ACH-1095, a compound shown be a potent inhibitor of HCV replication and which is preparing to enter Phase I clinical studies pending FDA consultation; and
Resistance-focused HCV program featuring compounds which, in pre-clinical studies have been shown to be several orders of magnitude more potent than other direct-acting inhibitors currently under development, and which may be effective in prevention and treatment of emerging resistant variants.
In addition, the Company will provide an update on partnering efforts related to its non-HCV assets, elvucitabine and ACH-702.
What They Do: Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease – HCV, HIV and resistant bacterial infections.
To read more about Achillion visit http://www.smallcapreview.com/achn.htm.
Global Industries, Ltd. (Nasdaq: GLBL) $7.12. Today announced that its majority Malaysian owned affiliate, Global Offshore Malaysia Sdn. Bhd. has been awarded a contract for transportation and installation of offshore facilities for projects in Malaysia. The contract, under which the actual scope of work will be defined annually, is initially estimated at around US$70 million for the first year, and has options for two 1-year extensions upon the expiry of the contract.
John Clerico, Global's Chairman and Chief Executive Officer, said: "This is the first contract we have been awarded in conjunction with our Malaysian partners, Kencana HL Sdn. Bhd. and we are very pleased that PETRONAS has shown such confidence in the Global - Kencana partnership's ability to carry out the significant scope of work involved with this project."
What They Do: Global Industries, Ltd. is a leading solutions provider of offshore construction, engineering, project management and support services including pipeline construction, platform installation and removal, deepwater/SURF installations, IRM, and diving to the oil and gas industry worldwide.
MDRNA, Inc. (Nasdaq: MRNA) $0.97. Today announced that the State Intellectual Property Office of the People's Republic of China (PRC) has issued a Notification of Granting Patent Rights for PRC 200480018784 which includes the use of nucleic acids, e.g., an siRNA, for the treatment of cancer. The patent describes modulation of claudins, which are proteins implicated in tumor progression and metastasis.
What They Do: MDRNA has a broad intellectual property estate that encompasses four key RNAi technology platforms: siRNA constructs, chemistry, nucleic acid delivery, and gene targets.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/. To follow us on Twitter visit http://twitter.com/SmallCapReview.
